Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Vertex Pharmaceuticals Inc

+ Add to Watchlist

VX1:GR

123.825 EUR 2.411 1.91%

As of 11:35:38 ET on 04/24/2015.

Snapshot for Vertex Pharmaceuticals Inc (VX1)

Open: 123.830 Day's Range: 123.337 - 125.732 Volume: 402
Previous Close: 126.236 52wk Range: 45.700 - 126.277 1-Yr Rtn: +162.57%

Stock Chart for VX1

No chart data available.
  • VX1:GR 123.825
  • 1D
  • 1M
  • 1Y
126.236
Interactive VX1 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for VX1

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -0.9770
Est. PEG Ratio -
Market Cap (M EUR) 30,165.42
Shares Outstanding (M) 243.61
30 Day Average Volume 539
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/29/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for VX1

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for VX1

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.

Jeffrey M Leiden "Jeff"Chairman/President/CEOIan F SmithExec VP/CFO
Stuart A ArbuckleExec VP/Chief Commercial OfcrDavid AltshulerExec VP:Global Research
More Company Profile & Key Executives for VX1

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil